Answers are grounded in this paper and cite their sources.
COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapyDear Editor, The novel coronavirus disease (COVID-19) and the related severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China in December 2019 and rapidly spread over the continents in a matter of months; it has dramatically changed not only our daily life, but also our daily dermatological practice.1,2 However, these forced changes have provided us food for thought.About 750 psoriatic patients assuming biological therapy currently refer to our psoriasis outpatient service, in Sant'Orsola-Malpighi University Hospital, Bologna (Italy), with an average of 80 patients visited weekly.
No takes yet. Share an insight, caveat, or question.
Filippi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: